Construction of the "Patient-Centered"Molecular Pathology Diagnostic Center
NCT ID: NCT01311388
Last Updated: 2011-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2010-08-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development and Application of Rapid Nucleic Acid Diagnostic Kits for Clinical Specimens
NCT01322685
A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture
NCT01255098
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis
NCT00173381
Establish a "Taiwan Rare Disorder Tissue Bank", to Collect and Repost Biological Samples and Disease Information From Patients With Rare Disorders
NCT01384305
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome
NCT00167024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators hope to find the biomarker of common tumors among Taiwanese in order to develop the tools of tumor screening, diagnosis, treatment methods and prediction prognosis
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* all kinds of cancer patients
Exclusion Criteria
* none cancer patients
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Medical University WanFang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Taipei Medical University-Center of Excellence For Cancer Research, TMU-CECR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wen-Ta Chiu
Role: PRINCIPAL_INVESTIGATOR
TMU-CECR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TMU-CECR
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
99049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.